Endo International (ENDP) Rating Increased to Sell at BidaskClub

Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.

A number of other research firms have also recently weighed in on ENDP. Barclays set a $9.00 price target on Endo International and gave the stock a “hold” rating in a report on Saturday, March 10th. BMO Capital Markets lowered their price target on Endo International from $10.00 to $9.00 and set a “market perform” rating for the company in a report on Monday, March 5th. JMP Securities cut Endo International from an “outperform” rating to a “market perform” rating in a report on Monday, February 26th. Cantor Fitzgerald set a $7.00 price target on Endo International and gave the stock a “hold” rating in a report on Tuesday, February 27th. Finally, Gabelli cut Endo International from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Three equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Endo International has an average rating of “Hold” and a consensus target price of $9.40.

NASDAQ ENDP opened at $6.20 on Wednesday. The firm has a market cap of $1.40 billion, a PE ratio of 1.91 and a beta of 0.34. The company has a debt-to-equity ratio of -1,161.84, a current ratio of 1.06 and a quick ratio of 0.88. Endo International has a twelve month low of $6.20 and a twelve month high of $6.41.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Tuesday, May 8th. The company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.12. The business had revenue of $700.53 million during the quarter, compared to analysts’ expectations of $691.94 million. Endo International had a positive return on equity of 143.46% and a negative net margin of 75.58%. The company’s revenue was down 32.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.23 EPS. equities analysts expect that Endo International will post 2.36 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA boosted its holdings in Endo International by 518.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,293,567 shares of the company’s stock valued at $19,564,000 after acquiring an additional 2,761,216 shares during the period. Diamond Hill Capital Management Inc. boosted its stake in shares of Endo International by 9.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 1,089,659 shares of the company’s stock valued at $6,473,000 after buying an additional 96,990 shares during the period. River & Mercantile Asset Management LLP boosted its stake in shares of Endo International by 32.7% in the 4th quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock valued at $3,679,000 after buying an additional 117,110 shares during the period. Alps Advisors Inc. boosted its stake in shares of Endo International by 48.8% in the 1st quarter. Alps Advisors Inc. now owns 457,917 shares of the company’s stock valued at $2,720,000 after buying an additional 150,078 shares during the period. Finally, Schroder Investment Management Group boosted its stake in shares of Endo International by 529.4% in the 1st quarter. Schroder Investment Management Group now owns 419,796 shares of the company’s stock valued at $2,494,000 after buying an additional 353,096 shares during the period. Institutional investors own 93.06% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit